|
|
Volumn 2007, Issue 395, 2007, Pages
|
|
Does erythropoietin have a dark side? Epo signaling and cancer cells.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CD131 ANTIGEN;
CSF2RB PROTEIN, HUMAN;
ERYTHROPOIETIN;
ERYTHROPOIETIN RECEPTOR;
JAK2 PROTEIN, HUMAN;
JANUS KINASE 2;
PHOSPHATIDYLINOSITOL 3 KINASE;
PROTEIN KINASE B;
RECOMBINANT PROTEIN;
STAT5 PROTEIN;
UNCLASSIFIED DRUG;
ANEMIA;
APOPTOSIS;
CANCER STEM CELL;
CELL DIFFERENTIATION;
CELL DIVISION;
CLASSIFICATION;
CLINICAL TRIAL;
DISEASE COURSE;
DRUG EFFECT;
ERYTHROPOIESIS;
HUMAN;
PHYSIOLOGY;
REVIEW;
SIGNAL TRANSDUCTION;
STRUCTURE ACTIVITY RELATION;
TREATMENT OUTCOME;
1-PHOSPHATIDYLINOSITOL 3-KINASE;
ANEMIA;
APOPTOSIS;
CELL DIFFERENTIATION;
CELL DIVISION;
CLINICAL TRIALS;
CYTOKINE RECEPTOR COMMON BETA SUBUNIT;
DISEASE PROGRESSION;
ERYTHROPOIESIS;
ERYTHROPOIETIN;
HUMANS;
JANUS KINASE 2;
MAP KINASE SIGNALING SYSTEM;
PROTO-ONCOGENE PROTEINS C-AKT;
RECEPTORS, ERYTHROPOIETIN;
RECOMBINANT PROTEINS;
SIGNAL TRANSDUCTION;
STAT5 TRANSCRIPTION FACTOR;
STRUCTURE-ACTIVITY RELATIONSHIP;
TREATMENT OUTCOME;
TUMOR STEM CELLS;
|
|
EID: 34548446804
PISSN: None
EISSN: 15258882
Source Type: Journal
DOI: 10.1126/stke.3952007pe38 Document Type: Review |
|
Times cited : (48)
|
|
References (37)
|
